<--- Back to Details
First PageDocument Content
Medicine / Immunosuppressants / Immunology / Clinical medicine / Monoclonal antibodies / Cytokines / Therapeutic antibodies / Autoimmune diseases / Infliximab / Anakinra / Adalimumab / Interferon
Date: 2015-08-17 11:45:03
Medicine
Immunosuppressants
Immunology
Clinical medicine
Monoclonal antibodies
Cytokines
Therapeutic antibodies
Autoimmune diseases
Infliximab
Anakinra
Adalimumab
Interferon

EAP Reimbursement Criteria for Frequently Requested Drugs

Add to Reading List

Source URL: www.health.gov.on.ca

Download Document from Source Website

File Size: 1,22 MB

Share Document on Facebook

Similar Documents

Pharmacology / Biotechnology / Health care / Recombinant proteins / Pharmaceutical industry / Immunosuppressants / Amgen / Biosimilar / Etanercept / Filgrastim / Hospira / Generic drug

BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, bi

DocID: 1rrNB - View Document

Multiple sclerosis / Medicine / Immunology / Clinical medicine / Autoimmune diseases / Neurological disorders / Neurology / Management of multiple sclerosis / Glatiramer acetate / Immunosuppressants / McDonald criteria / Diagnostic criteria for MS

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2

DocID: 1rmwo - View Document

Medicine / Immunosuppressants / Immunology / Clinical medicine / Monoclonal antibodies / Cytokines / Therapeutic antibodies / Autoimmune diseases / Infliximab / Anakinra / Adalimumab / Interferon

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

Medicine / Clinical medicine / Immunology / Immunosuppressants / RTT / Biotechnology / Autoimmune diseases / Arthritis / Certolizumab pegol / TNF inhibitor / UCB / Anakinra

UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include:  Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certol

DocID: 1rakB - View Document

Medicine / Immunology / Clinical medicine / Health care / Immunosuppressants / Biotechnology / Monoclonal antibodies / Immune system / Immunogenicity / Autoimmunity / Infliximab / Arthritis

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qY7G - View Document